Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491626 | 0.87 | ACHE (0.48) | ACHEENPP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8814719 | 0.87 | ACHE (0.48) | ACHEENPP2ABATKDM4ECASP6 | |
| SCHEMBL10167473 | 0.87 | ACHE (0.48) | ACHEENPP2ABATKDM4ECASP6 | |
| SCHEMBL9396245 | 0.82 | ACHE (0.48) | ACHEENPP2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7697347 | 0.82 | LOXL2 (0.36) | ENPP2ABATCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19078822 | 0.78 | LOXL2 (0.40) | ACHEENPP2ABATKDM4ECASP6 | |
| SCHEMBL2028886 | 0.76 | ACHE (0.39) | ACHEENPP2ABATKDM4ECASP6 | |
| SCHEMBL15651082 | 0.76 | ACHE (0.39) | ACHECYP1A2CYP2D6CYP2C19THPO | |
| SCHEMBL4335695 | 0.76 | PNMT (0.46) | ACHE | |
| SCHEMBL16953198 | 0.76 | ACHE (0.39) | ACHEKDM4ECASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781563-B1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20210276994-A1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2021-09-09 | — | — | US | disclosed |
| EP-2706853-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9290490-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| CN-102858767-B | As the aminopyrimidine of SYK inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-05-29 | — | — | US | disclosed |
| EP-2706853-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| CN-102858767-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | disclosed |
| WO-2012154519-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ACHE 1312/4885ENPP2 1053/4885ABAT 372/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | ACHE 1312/4885ENPP2 1053/4885ABAT 372/4885 |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ACHE 1794/4885ENPP2 938/4885ABAT 524/4885 |
| US-20210276994-A1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | PGK1, HK1, PDXK | ACHE 4721/4885ENPP2 2613/4885ABAT 4359/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ACHE 1312/4885ENPP2 1053/4885ABAT 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.